The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer

Faleiro, Inês; Apolónio, Joana; Price, Aryeh J.; De Mello, Ramon Andrade; Roberto, Vânia; Tabori, Uri; Castelo-Branco, Pedro

http://hdl.handle.net/10400.1/12962

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
12962 - FAleiro et al future Oncology.pdf		2.2 MB	Adobe PDF	Download

Send Feedback

Authors

Faleiro, Inês

Apolónio, Joana

Price, Aryeh J.

De Mello, Ramon Andrade

Roberto, Vânia

Tabori, Uri

Castelo-Branco, Pedro

Abstract(s)

Aim: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. Materials & methods: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). Results: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis. Discussion: We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples. Conclusion: Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.